Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MGNX's Cash to Debt is ranked higher than
97% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. MGNX: No Debt )
MGNX' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Equity to Asset 0.83
MGNX's Equity to Asset is ranked higher than
84% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. MGNX: 0.83 )
MGNX' s 10-Year Equity to Asset Range
Min: -0.26   Max: 0.83
Current: 0.83

-0.26
0.83
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
66% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
MGNX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 12.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 9.51
MGNX's Operating margin (%) is ranked higher than
89% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. MGNX: 9.51 )
MGNX' s 10-Year Operating margin (%) Range
Min: -80.16   Max: 12.86
Current: 9.51

-80.16
12.86
Net-margin (%) 9.51
MGNX's Net-margin (%) is ranked higher than
89% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. MGNX: 9.51 )
MGNX' s 10-Year Net-margin (%) Range
Min: -80.16   Max: 13.1
Current: 9.51

-80.16
13.1
ROE (%) 6.31
MGNX's ROE (%) is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. MGNX: 6.31 )
MGNX' s 10-Year ROE (%) Range
Min: -38.27   Max: -0.74
Current: 6.31

-38.27
-0.74
ROA (%) 4.67
MGNX's ROA (%) is ranked higher than
91% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. MGNX: 4.67 )
MGNX' s 10-Year ROA (%) Range
Min: -25.57   Max: 14.36
Current: 4.67

-25.57
14.36
ROC (Joel Greenblatt) (%) 164.43
MGNX's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. MGNX: 164.43 )
MGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -648.31   Max: 502.14
Current: 164.43

-648.31
502.14
» MGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MGNX Guru Trades in Q2 2014

George Soros 19,488 sh (New)
First Eagle Investment 334,285 sh (New)
John Griffin 900,000 sh (unchged)
Steven Cohen 2,017,066 sh (unchged)
» More
Q3 2014

MGNX Guru Trades in Q3 2014

Ronald Muhlenkamp 16,975 sh (New)
John Griffin 1,350,000 sh (+50.00%)
George Soros 19,488 sh (unchged)
First Eagle Investment 334,285 sh (unchged)
Steven Cohen 1,521,100 sh (-24.59%)
» More
Q4 2014

MGNX Guru Trades in Q4 2014

Paul Tudor Jones 9,954 sh (New)
Julian Robertson 185,775 sh (New)
Stanley Druckenmiller 472,500 sh (New)
Steven Cohen 1,938,771 sh (+25.99%)
First Eagle Investment 339,285 sh (+1.50%)
Steven Cohen 1,538,771 sh (+1.16%)
John Griffin 1,350,000 sh (unchged)
George Soros 19,488 sh (unchged)
Ronald Muhlenkamp 16,725 sh (-1.47%)
» More
Q1 2015

MGNX Guru Trades in Q1 2015

Ronald Muhlenkamp 66,405 sh (+297.04%)
Steven Cohen 2,350,951 sh (+52.78%)
Paul Tudor Jones 14,089 sh (+41.54%)
First Eagle Investment 393,181 sh (+15.89%)
Julian Robertson 185,775 sh (unchged)
George Soros 19,488 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Stanley Druckenmiller 472,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Macrogenics Inc

Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC
According to GuruFocus list of three-year lows, Knowles Corporation, Macrogenics Inc., MiX Telematics Ltd. and Education Management Corp have all reached their three-year lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 198.60
MGNX's P/E(ttm) is ranked higher than
86% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MGNX: 198.60 )
MGNX' s 10-Year P/E(ttm) Range
Min: 185.29   Max: 230.89
Current: 198.6

185.29
230.89
PE(NRI) 192.80
MGNX's PE(NRI) is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MGNX: 192.80 )
MGNX' s 10-Year PE(NRI) Range
Min: 181.81   Max: 226.56
Current: 192.8

181.81
226.56
P/B 4.10
MGNX's P/B is ranked higher than
74% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. MGNX: 4.10 )
MGNX' s 10-Year P/B Range
Min: 3.33   Max: 12.85
Current: 4.1

3.33
12.85
P/S 8.60
MGNX's P/S is ranked higher than
76% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. MGNX: 8.60 )
MGNX' s 10-Year P/S Range
Min: 1.12   Max: 20.49
Current: 8.6

1.12
20.49
EV-to-EBIT 66.84
MGNX's EV-to-EBIT is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MGNX: 66.84 )
MGNX' s 10-Year EV-to-EBIT Range
Min: -38   Max: 1225.7
Current: 66.84

-38
1225.7
Current Ratio 11.13
MGNX's Current Ratio is ranked higher than
88% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MGNX: 11.13 )
MGNX' s 10-Year Current Ratio Range
Min: 1.35   Max: 11.13
Current: 11.13

1.35
11.13
Quick Ratio 11.13
MGNX's Quick Ratio is ranked higher than
88% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MGNX: 11.13 )
MGNX' s 10-Year Quick Ratio Range
Min: 1.35   Max: 11.13
Current: 11.13

1.35
11.13
Days Sales Outstanding 6.01
MGNX's Days Sales Outstanding is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. MGNX: 6.01 )
MGNX' s 10-Year Days Sales Outstanding Range
Min: 11.7   Max: 22.41
Current: 6.01

11.7
22.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.30
MGNX's Price/Net Cash is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. MGNX: 4.30 )
MGNX' s 10-Year Price/Net Cash Range
Min: 4.36   Max: 9.94
Current: 4.3

4.36
9.94
Price/Net Current Asset Value 4.30
MGNX's Price/Net Current Asset Value is ranked higher than
88% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. MGNX: 4.30 )
MGNX' s 10-Year Price/Net Current Asset Value Range
Min: 4.26   Max: 9.52
Current: 4.3

4.26
9.52
Price/Tangible Book 4.00
MGNX's Price/Tangible Book is ranked higher than
78% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. MGNX: 4.00 )
MGNX' s 10-Year Price/Tangible Book Range
Min: 4.17   Max: 8.76
Current: 4

4.17
8.76
Price/Median PS Value 1.70
MGNX's Price/Median PS Value is ranked higher than
71% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. MGNX: 1.70 )
MGNX' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 3.77
Current: 1.7

0.23
3.77
Price/Graham Number 4.10
MGNX's Price/Graham Number is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MGNX: 4.10 )
MGNX' s 10-Year Price/Graham Number Range
Min: 4.14   Max: 4.14
Current: 4.1

Earnings Yield (Greenblatt) 1.40
MGNX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. MGNX: 1.40 )
MGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.5
Current: 1.4

0.1
1.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:M55.Germany,
Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MACROGENICS INC Financials May 15 2015
MacroGenics Announces Presentation at ASCO Annual Meeting 2015 May 13 2015
MacroGenics Announces Presentation at ASCO Annual Meeting 2015 May 13 2015
MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results May 06 2015
MacroGenics misses 1Q profit forecasts May 06 2015
MacroGenics misses 1Q profit forecasts May 06 2015
MACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results May 06 2015
MacroGenics Announces Date of First Quarter 2015 Financial Results Conference Call Apr 29 2015
MacroGenics Announces Date of First Quarter 2015 Financial Results Conference Call Apr 29 2015
MacroGenics Announces Participation in Two Investor Conferences in May Apr 28 2015
MacroGenics Announces Participation in Two Investor Conferences in May Apr 28 2015
MacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting Apr 20 2015
MacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting Apr 20 2015
MacroGenics Announces Presentations at AACR Annual Meeting 2015 Apr 16 2015
MacroGenics Announces Presentations at AACR Annual Meeting 2015 Apr 16 2015
MacroGenics to Present at the 14th Annual Needham Healthcare Conference Apr 07 2015
MacroGenics to Present at the 14th Annual Needham Healthcare Conference Apr 07 2015
MacroGenics Slumps: MGNX Falls 7.5% in Session - Tale of the Tape Mar 23 2015
MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK